Inclusion Criteria:
- Male or female subjects aged greater than or equal to (>=) 18 years
- Tumor determined to be positive for PD-L1 expression per the evaluation of a central
laboratory
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1
- At least 1 lesion that can be measured.
- Subjects with histologically confirmed metastatic or recurrent non-small cell lung
cancer (NSCLC)
- Subjects must not have received any treatment for systemic lung cancer, and have an
estimated life expectancy of more than 12 weeks
- Other protocol defined criteria could apply
Exclusion Criteria:
- Subjects whose disease harbors an activating epidermal growth factor receptor (EGFR)
mutation, or an anaplastic lymphoma kinase (ALK) rearrangement
- Prior therapy with any antibody or drug targeting T cell coregulatory proteins,
concurrent anticancer treatment, or immunosuppressive agents
- Subjects with known severe hypersensitivity reactions to monoclonal antibodies,
history of anaphylaxis, or uncontrolled asthma, and persisting toxicity related to
prior therapy of Grade greater than (>) 1
- Subjects with brain metastases are excluded, except those meeting the following
criteria: brain metastases that have been treated locally and are clinically stable
for at least 2 weeks prior to enrollment, subjects must be either off steroids or on
a stable or decreasing dose of less than (<) 10 mg daily prednisone (or equivalent),
and do not have ongoing neurological symptoms that are related to the brain
localization of the disease
- Other protocol defined criteria could apply
Minimum Eligible Age: 18 Years
Maximum Eligible Age: N/A
Eligible Gender: Both
Best Overall Response (BOR)
Overall Survival (OS)
Change from baseline in European Quality Of Life 5-dimensions (EQ-5D-5L) Health Outcome Questionnaire
Change from baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status
Change from baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13)
Number of subjects with Treatment-Emergent Adverse Events (TEAEs) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03